Backgrounds and Aims: Previous studies have investigated that sarcopenia is associated with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, and fibrosis in NAFLD. The study aims to investigate the risk for NAFLD, especially NAFLD-related significant fibrosis among subjects with sarcopenia. Methods: We searched electronic databases until 30, September 2017 and reviewed literature extensively. Effect estimates were pooled using random effect models regarding the risk for NAFLD and fixed effect models concerning the risk for significant fibrosis among sarcopenia patients. Sensitivity analysis was performed for the risk of NAFLD. Results: We identified 6 studies. Our results showed that subjects with sarcopenia exhibited an increased risk for NAFLD compared to those without sarcopenia (OR 1.29, 95% CI 1.12-1.49) with heterogeneity among the individual studies (I-2 = 61%). And the risk for NAFLD-related significant fibrosis appeared to be more pronounced in sarcopenia patients (OR 1.57, 95% CI 1.29-1.90) with an I-2 of 0%. Sensitivity analysis revealed that neither the direction nor the magnitude of the estimated pooled results for NAFLD was obviously affected. Furthermore, the pooled ORs were both close to initial analysis when omitting the study by Hong et al. [Hepatology 2014; 59: 1772-1778] (OR 1.24, 95% CI 1.111.39, I-2 = 47%) or by Hashimoto et al. [Endocr J 2016; 63: 877884] (OR 1.33, 95% CI 1.11-1.59, I-2 = 67%), which were considered sources of heterogeneity. Conclusions: Our analysis demonstrated that sarcopenia served not only as a risk factor for the onset of NAFLD but also related to the progression of NAFLD-related significant fibrosis. (C) 2018 S. Karger AG, Basel
[1]Soochow Univ, Affiliated Hosp 1, Dept Endocrinol, Suzhou 215006, Peoples R China;
[2]Wenzhou Med Univ, Affiliated Hosp 1, Dept Endocrinol, Wenzhou, Peoples R China;
[3]Wenzhou Med Univ, Affiliated Hosp 1, Liver Res Ctr, Dept Hepatol, 2 Fuxue Lane, Wenzhou 325000, Peoples R China;
[4]Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou, Peoples R China;
[5]Wenzhou Med Univ, Sch Clin Med Sci 2, Wenzhou, Peoples R China;
[6]Fudan Univ, State Key Lab Genet Engn, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China;
[7]Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
(8.0+极速模式)